These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 36774542)

  • 1. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
    Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
    Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
    Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
    J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice.
    Bauri R; Bele S; Edelli J; Reddy NC; Kurukuti S; Devasia T; Ibrahim A; Rai V; Mitra P
    Am J Physiol Cell Physiol; 2024 Jul; 327(1):C74-C96. PubMed ID: 38738303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A; Rosenkilde MM; Gasbjerg LS
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-mediated control of cardiac energy metabolism.
    Chan JSF; Shafaati T; Ussher JR
    J Endocrinol; 2024 Oct; 263(1):. PubMed ID: 39013412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
    Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
    Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide.
    Khan R; Tomas A; Rutter GA
    Peptides; 2020 Mar; 125():170201. PubMed ID: 31751656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
    Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
    Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
    Usui R; Yabe D; Seino Y
    J Diabetes Investig; 2019 Jul; 10(4):902-905. PubMed ID: 30637966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological antagonism of the incretin system protects against diet-induced obesity.
    Svendsen B; Capozzi ME; Nui J; Hannou SA; Finan B; Naylor J; Ravn P; D'Alessio DA; Campbell JE
    Mol Metab; 2020 Feb; 32():44-55. PubMed ID: 32029229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.